Crystalys Therapeutics
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
$130MSeries B
Role not disclosedLoading investors…
Activity from announced rounds
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
Developing transformative, best-in-class neuropsychiatric therapies
Pitching SR One? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room